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Background and Objective: The influence of genes on human lifespan is mediated by
biological processes that characterize body’s functioning. The age trajectories of these
processes contain important information about mechanisms linking aging, health, and
lifespan. The objective of this paper is to investigate regularities of aging changes in
different groups of individuals, including individuals with different genetic background,
as well as their connections with health and lifespan. Data and Method: To reach this
objective we used longitudinal data on four physiological variables, information about
health and lifespan collected in the Framingham Heart Study (FHS), data on longevity
alleles detected in earlier study, as well as methods of statistical modeling. Results: We
found that phenotypes of exceptional longevity and health are linked to distinct types of
changes in physiological indices during aging. We also found that components of aging
changes differ in groups of individuals with different genetic background. Conclusions:
These results suggest that factors responsible for exceptional longevity and health are
not necessary the same, and that postponing aging changes is associated with extreme
longevity. The genetic factors which increase lifespan are associated with physiological
changes typical of healthy and long-living individuals, smaller mortality risks from cancer
and CVD and better estimates of adaptive capacity in statistical modeling. This indicates
that extreme longevity and health related traits are likely to be less heterogeneous
phenotypes than lifespan, and studying these phenotypes separately from lifespan may
provide additional information about mechanisms of human aging and its relation to chronic
diseases and lifespan.
Keywords: age trajectories, physiological variables, longevity genes, genetic dose, integrative genetic mortality
model
INTRODUCTION
The influence of genes on lifespan is mediated by biological vari-
ables which integrate responses to numerous external and internal
challenges to maintain functioning of an organism’s life support-
ing and reproductive machineries. Some of these variables are
measured in longitudinal studies of aging, health and longevity.
To mediate genetic effects on lifespan, these variables have to
be associated with lifespan as well. Such associations have been
established in epidemiological studies for a number of physi-
ological variables where their roles as risk factors for all-cause
mortality or chronic degenerative diseases have been investigated.
Among many other variables, body mass index (BMI), diastolic
blood pressure (DBP), serum cholesterol (SCH), and ventricular
rate deserve particular attention because their typical average age
trajectories are non-monotonic and their associations with all-
cause mortality have been widely studied. Specifically, the effect
of BMI on risk of diseases and mortality was intensively studied
in connection with metabolic syndrome. Freedman et al. (2006)
showed that the connection between BMI and mortality risks is
generally J-shaped for both genders and different age groups. The
authors also found that this risk function changes with age. The
relationships between mortality risk and BMI were also assessed
(see Zhou, 2002; Gu et al., 2006; Gelber et al., 2007; Klenk et al.,
2009, among others).
The connection between DBP and all-cause mortality risk
has been investigated to better understand factors and mech-
anisms of cardiovascular diseases (CVD) (Cruickshank, 1988,
2003; Staessen, 1996). Special attention has been paid to the
J-shape of the risk function (see Isles and Hole, 1992; Alderman,
1996; Cruickshank, 2003; Messerli and Panjrath, 2009; Grassi
et al., 2010, among others). Franklin et al. (2001) studied changes
in this risk function with age. Boshuizen et al. (1998) studied
the connection of blood pressure and mortality risk among the
elderly. Questions of optimal blood pressure were discussed by
Onrot (1993) and Townsend (2005), among others.
Anderson et al. (1987) evaluated the connection between
SCH and mortality using 30 years of follow-up data from the
Framingham Heart Study (FHS). The authors found that a 1%
increase in total cholesterol produced a 2% increase in coronary
heart disease incidence among individuals between 60 and 70
years of age. Kronmal et al. (1993) found that the relationship
between total cholesterol level and all-causemortality was positive
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at age 40 years, negligible at ages 50–70 years, and negative at age
80 years. Manolio et al. (1992) and Weverling-Rijnsburger et al.
(1997, 2003) showed that CVD in old age was independent of total
SCH levels. Weverling-Rijnsburger et al. (1997) proposed that this
could be a result of selective mortality of those with the high-
est cholesterol levels in middle age. Weverling-Rijnsburger et al.
(1997) and Schatz et al. (2001) showed that low total SCH levels
are associated with higher all-cause mortality in the oldest old.
The relationship between SCH and all-cause mortality was also
studied by Chyou and Eaker (2000) and Li et al. (2004a,b), among
others.
The effects of resting heart rate (also called ventricular rate,
VR) on cardiovascular mortality have been discussed in Kannel
et al. (1987). Mensink and Hoffmeister (1997) and Benetos et al.
(1999) investigated the effects of resting heart rate on all-cause
mortality. The connection between heart rate and mortality in
the elderly has also been investigated by Cacciatore et al. (2007).
Kuzuya et al. (2008) found a J-shaped relationship between rest-
ing pulse rate and all-cause mortality in community dwelling
older people with disabilities. Böhm et al. (2012) showed that rest-
ing heart rate in clinical conditions is associated with all-cause
mortality, disability, and cognitive decline.
The results described above indicate that studying aging
related changes in physiological variables as well as genetic fac-
tors involved in their regulation using available longitudinal data
could make substantial contributions to clarifying mechanisms
linking aging, health, and longevity in humans, and provide use-
ful insights into alternative strategies for improvement of people’s
health by postponing the aging process (Kristjuhan, 2012). Note
that none of the studies mentioned above performed either sys-
tematic analyses of age patterns of corresponding variables, or
their roles in mediating genetic influences on lifespan. The lon-
gitudinal data on aging, health, and lifespan collected in the FHS
contain valuable information on biennial measurements of these
physiological variables during the life courses of study partici-
pants, detailed data on their genetic background, as well as data
on health and survival outcomes which can be used for testing
the ability of these variables to mediate genetic influences on
lifespan.
In this paper we evaluate and discuss the properties of the
average age trajectories of the four physiological indices described
above, evaluate the connections of the shapes of these trajectories
to lifespan, and individuals’ health status. We also evaluate how
the different doses of pro-survival alleles carried by study partic-
ipants are associated with the age patterns of their physiological
variables. Using a stochastic process model (Yashin et al., 2007a),
we evaluate hidden components of the process that drive aging
related changes in physiological variables.
DATA ANDMETHODS
THE FRAMINGHAM HEART STUDY (FHS) DATA
The FHS Original cohort was launched at Exam 1 in 1948
and has continued with biennial examinations to the present
(30 exams to date; data from exams 1–28 were available for
this study). The FHS Original cohort consists of 5209 respon-
dents (55% females) aged 28–62 years at baseline residing in
Framingham, Massachusetts, between 1948 and 1951. Nearly all
subjects were Caucasians. The examination included an interview,
physical examination, and laboratory tests. Individual informa-
tion on the SNP genotyping and phenotypic traits collected in
the Framingham Study was obtained through the dbGaP web-
site. The data on phenotypic traits collected in the Original FHS
cohort over 60 years and relevant to our analyses include: ages
at disease onsets for cancer, CVD and diabetes, causes of death,
lifespan, and various factors that may affect disease risk and prog-
nosis including BMI (data available at exams 1, 4, 5, and 10–28),
DBP (exams 1–28), SCH (exams 1–11, 13–15, 20, and 22–28), VR
(exams 4–28), age at exam, sex, birth cohort, and smoking status
(exams 1, 4, 5, 7–15, and 17–28).
The occurrence of diseases (CVD and cancer) and death
(including information on the cause of death coded as death from
cancer, CVD, and all other or unknown causes) has been fol-
lowed through continuous surveillance of hospital admissions,
death registries, clinical exams, and other sources, so that all the
respective events are included in the study. We used data on first
occurrence of CVD (defined by the FHS investigators as having
any of the following: coronary heart disease, intermittent clau-
dication, congestive heart failure, or stroke/transient ischemic
attack) and cancer from the follow-up data, and data on cur-
rent diabetes status (defined by the FHS investigators as a level
of blood glucose exceeding 140mg/dl and/or taking insulin or
oral hypoglycemics) in exams in analyses involving the onset of
“unhealthy life” (see below).
We also used information about the distribution of 27 “pro-
survival” alleles among participants of the FHS Original cohort.
Figure 1 shows distribution of the numbers of these alleles in
the sample of genotyped individuals in the FHS Original cohort.
These genetic variants showed highly significant joint influence
on lifespan in our recent study (Yashin et al., 2012c). They were
selected out of 550,000 SNPs in 1471 genotyped participants of
the FHS Original cohort as described in Yashin et al. (2012c).
Table 1 below shows essential information about the 27 SNPs and
FIGURE 1 | Distribution of the numbers of pro-survival alleles out of 27
of such alleles selected in Yashin et al. (2012c) in the sample of
genotyped individuals in the FHS Original cohort.
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their closest genes. More detailed information about the genes
closest to the 27 SNPs, including their biological functions and
links to aging and disease phenotypes, as found in current lit-
erature, is provided in Yashin et al. (2012c). In brief, of the 27
SNPs, 16 were located within functioning genes, and all these
SNPs but one were intronic. Overall, these genes have been linked
in the literature to multiple phenotypes, although they were more
often involved in cancer and brain disorders. While some of the
genes, in which the selected SNPs are located, may produce spe-
cific physiological effects, none of the 27 SNPs identified in Yashin
et al. (2012c) has been found so far to be individually significantly
associated with BMI, DBP, SCH, or VR.
EMPIRICAL ANALYSES
First, we calculated empirical estimates of the mean values of
four physiological indices (BMI, DBP, SCH, and VR) in age
groups<35, 35–39, . . .., 85–89, and 90+ years for all participants
of the Original FHS cohort (males and females combined) using
pooled data on measurements from all exams.
Second, we selected groups of short-lived individuals (those
dying at ages 75 or earlier; censored individuals are excluded from
this group) and 100 longest lived individuals (which is equivalent
to individuals with lifespan exceeding 97.44 years) and evaluated
average values of physiological indices in the same age groups for
these individuals using pooled data on measurements from all
exams.
Third, we used data on the first occurrence of CVD and can-
cer from the follow-up data, and data on current diabetes status
from the exams to calculate ages at onset of “unhealthy life”
defined as the minimum of ages of occurrence of these dis-
eases. Then we evaluated average age trajectories of physiological
indices in the same age groups described above for “unhealthy”
(those with cancer, CVD, or diabetes) and “healthy” (those free
of these three diseases) individuals. Measurements of physiolog-
ical indices before the onset of any of these diseases contributed
to the “healthy” trajectory and those after the onset of any of the
diseases contributed to the “unhealthy” trajectory. Note that aver-
age values based on less than 10 observations are not shown in all
figures.
Fourth, we evaluated average age trajectories in the same age
groups for carriers of different numbers of alleles among the 27
pro-survival alleles selected as described in Yashin et al. (2012c).
Note that the identity of SNPs was not important in this selection
procedure. We calculated the total number of pro-survival alleles
in the genomes of individuals using data on 27 SNPs selected in
Yashin et al. (2012c). For each individual and for each of these 27
SNPs, we created a dichotomous variable equaling 1 if the indi-
vidual has respective minor allele and 0 if he/she is a carrier of
major allele homozygote for respective SNP. Then we created a
variable counting the number of 1’s for each individual (that is,
the number of such minor alleles in these 27 SNPs, which could
be any number from 0 to 27). The genotyped sample was divided
into two sub-groups, the first containing individuals having less
than 14minor alleles and the second consisting of those having
14 or more minor alleles. For the sake of convenience, we will
refer to these sub-groups as the (<14)- and the (≥14) groups,
respectively. Then the age trajectories of average values of four
physiological indices were calculated for individuals in these two
sub-groups. Note that all analyses related to these alleles are based
on data from 1471 genotyped participants.
Fifth, we estimated average trajectories among “unhealthy”
and “healthy” carriers of different numbers of pro-survival alleles,
as described above.
Sixth, we compared average trajectories among carriers and
non-carriers of the APOE e4 allele. These calculations are based
on data on APOE polymorphisms available for 1258 participants
of the original FHS cohort.
Finally, we evaluated associations of the “genetic dose” with
mortality rates by cause in the Cox proportional hazards model.
“Genetic dose” or “polygenic score” is defined here as a vari-
able calculating the number of pro-survival alleles [out of the 27
alleles from Yashin et al. (2012c)] in the genomes of 1471 geno-
typed individuals from the Original FHS cohort. The model was
adjusted for sex, birth cohort, and smoking status (ever/never
smoked). Age at the biospecimen collection available for the
genotyped individuals was used as the left truncation in the Cox
model. The model was applied to data on total mortality as well
as mortality by cause (cancer, CVD, and all other or unknown
causes, denoted as “Other” in Table 3).
All calculations mentioned above have been performed using
SAS 9.3. Graphical output was prepared in MATLAB R2012a.
Table 2 shows subject characteristics in the specific analyses
described above.
ADVANCED STATISTICAL ANALYSES USING THE STOCHASTIC
PROCESS MODEL
We illustrated how different aging-related characteristics in car-
riers of different numbers of pro-survival alleles may jointly
contribute to the patterns of mortality rates as well as the tra-
jectories of physiological variables applying the stochastic process
model of aging (Yashin et al., 2007a) to data on four physiologi-
cal indices (BMI, DBP, SCH, and VR) and total mortality in the
1471 genotyped individuals from the original FHS cohort. Note
that data on genotyped and non-genotyped individuals can be
analyzed jointly in the version of the stochastic process model
described in Arbeev et al. (2009) but such analyses are beyond
the scope of this paper. Some concepts and ideas about the pro-
cess of aging that are used in the stochastic process model are
briefly outlined in section “The need for comprehensive inte-
grative analyses of longitudinal data.” Technical details about
the specific version of the model used in this paper are given
below.
Stochastic dynamics of individual age trajectories of physiological
indices
The version of stochastic process model (Yashin et al., 2007a,
2012a), can be used to provide information about adaptive
mechanisms forming the age trajectories of average physiological
indices. In this model the individual dynamics of one phys-
iological index is described by stochastic differential equation
dYt = a(t)
(
Yt − f1(t)
)
dt + B(t)dWt, Y0 (1)
Here Yt is the value of a particular physiological index at age
t in an arbitrarily chosen individual. In contrast to traditional
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Table 2 | Characteristics of study subjects.
Study sample Baseline age % Females Sample size
Mean St. Dev. Min Max
TOTAL SAMPLE
44.1 8.60 28 62 55.2% 5209
SHORT- VS. LONG-LIVED
Short-lived 44.0 8.35 28 62 42.4% 1801
Long-lived 47.8 6.58 37 62 85.0% 100
“UNHEALTHY” VS. “HEALTHY”
“unhealthy” 44.1 8.61 28 62 52.7% 4291
“healthy” 44.2 8.55 29 62 66.4% 788
CARRIERS OF DIFFERENT NUMBER OF PRO-SURVIVAL ALLELES
<14 42.0 7.32 30 61 54.4% 721
≥14 36.0 4.50 29 55 65.7% 750
CARRIERS (“E4”) AND NON-CARRIERS (“NOT E4”) OF THE APOE E4 ALLELE
e4 37.9 5.96 28 57 66.1% 277
not e4 37.6 5.66 29 57 63.1% 981
“UNHEALTHY” AMONG CARRIERS OF DIFFERENT NUMBER OF PRO-SURVIVAL ALLELES
“unhealthy”, <14 41.8 7.27 30 61 52.3% 637
“unhealthy”, ≥14 35.9 4.46 29 54 63.4% 658
Notes: Short-lived are those dying at ages below 75, long-lived are those with 100 longest life spans; see details in the text. “Unhealthy” are those who had onset
of at least one of the three diseases (cancer, CVD, diabetes) during the follow-up period; “healthy” are those free of such disease during the follow-up period;
see more details on calculations of average trajectories in “unhealthy” and “healthy” individuals in the text. Carriers of different numbers of pro-survival alleles are
defined based on the 27 SNPs identified in Yashin et al. (2012c); see details on the selection procedure in the text.
approaches used for analyzing longitudinal data with health or
survival outcomes the description of the data in our model
includes additional unobserved variables having important bio-
logical meaning for the aging process. The coefficient B(t)
characterizes the contribution of random external disturbances
described by a Wiener process,Wt . Function f1(t) describes effect
of allostatic adaptation, i.e., integrated effect of persistent external
or internal disturbances which Yt is forced to follow by homeo-
static forces. Taking this effect into account is especially important
in analyses of longitudinal data on aging, health and longevity
in which measurements of external disturbances are absent or
limited. This adaptation aims at achieving stability of key bio-
logical variables (not described here), through physiological or
behavioral change. The strength of homeostatic forces is char-
acterized by the negative feedback coefficient, a(t). According to
(1) the age trajectory of physiological indices Yt tends to follow
function f1(t), i.e., adapt to changes in f1(t). An ability to adapt
depends on the absolute values of a(t). Age-related changes in
these coefficients characterize changes in adaptive capacity with
age. Specifically, a(t) regulates the age trajectory of the physiolog-
ical index approximated by Yt , i.e., it characterizes the rate of the
adaptive response for any deviation of a physiological index from
the state f1(t) which an organism tends to follow. For example,
in a simplified one-dimensional case, when B(t) = 0, for all t, in
Equation (1), and constant negative a(t) = a for all t, the param-
eter a is the coefficient of negative feedback in the equation for
Yt , which keeps the trajectory Yt close to f1(t). When f1(t) = f1,
constant for all t, the value of Yt asymptotically approaches f1. In
case of non-zero disturbances, the higher the absolute value of a,
the closer Yt is to f1, and the faster Yt tends to f1. That is why the
value a(t) characterizes adaptive capacity. Practical estimation of
the changes in adaptive capacity with age involves maximization
of the likelihood function of the data in which a(t) is described
as parametric functions of age. The random variable Y0 describes
the initial value of physiological index, which is assumed to be
independent of Wt for each t ≥ 0. The introduction of f1(t) and
a(t) into the model facilitates the biological interpretation of the
results of statistical analyses of longitudinal data.
Conditional risk function (conditional mortality rate)
Note that individual trajectories of physiological variables must
be stopped at random time T describing lifespan of an individual.
The probability distribution of this stopping time is characterized
by conditional mortality rate given the value of the physiologi-
cal index. This conditional mortality rate is represented by the
quadratic form:
μ (t,Yt) = μ0(t) + Q(t)
(
Yt − f0(t)
)2
(2)
The term μ0(t) (the baseline mortality rate) is a function of
age. It shows how the total mortality rate would change if a
corresponding physiological index Yt followed the optimal tra-
jectory f0(t). The function f0(t) is associated with the notion of
the age-dependent “norm” in the model. The positive function
Q(t) shows how the steepness of the parabola Q(t)
(
Yt − f0(t)
)2
changes with increasing age.
The model described above takes into account the fact that
available longitudinal data do not contain records characterizing
when, how, and how long external disturbances affected individ-
uals during their life course. The use of the notions of allostasis
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and allostatic adaptation helps us understand how persistent
unfavorable conditions get “under the skin” of affected person,
increasing his/her susceptibility to diseases and death (McEwen,
2012). Many such conditions affect set-points of physiological
homeostasis changing physiological balance from the “normal,”
f0(t) to “abnormal,” f1(t) = f0(t) state. These effects, represented
in Equation (1) can be estimated from the FHS data thereby pro-
viding indirect evaluation of the effects of external disturbances
without measuring them.
Version of model used in application to FHS data
We applied a discrete-time version (see Yashin et al., 2007b) of the
general model (1)–(2) (with values of a physiological index eval-
uated at one-year age intervals using respective observations in
the adjacent FHS exams) with specification of respective compo-
nents as follows. We used a constant diffusion B(t) = σ1; a linear
function for the adaptive capacity a(t): a(t) = aY + bY t; a linear
function for the quadratic hazard term Q(t): Q(t) = aQ + bQt,
and the Gompertz function for the baseline hazardμ0(t):μ0(t) =
aμ0exp(bμ0 t). Initial values Y0 are assumed normally distributed,
N(f1(t0), σ0).
To evaluate the “optimal” trajectories f0(t), we calculated the
average age trajectories of physiological variables for long-lived
individuals (those with lifespan exceeding 90 years) in the origi-
nal FHS cohort and fitted these trajectories by cubic polynomials
using the Curve Fitting Toolbox in MATLAB. The fitted curves
were used as the estimates of the “optimal” trajectories f0(t)
[see motivation for such specification in Yashin et al. (2012b)].
Note that longitudinal observations in long-lived individuals
are available only starting at ages 40 and above. Therefore, we
restricted applications of our model to observations at ages 40
and above.
Taking into account the possibility that the homeostatic regu-
lation forces the trajectory of physiological variables to the values
different from the optimal values represented by f0(t) and that this
difference can be age-dependent, we specified the function f1(t) as
f1(t) = f0(t) + f0(t), where  f0(t) = af0 + bf0 t.
Details of the likelihood maximization procedure can be
found in Yashin et al. (2007a,b). The likelihood maximization
was performed using the constrained optimization procedure of
MATLAB’s Optimization Toolbox. The constrained maximiza-
tion algorithm was used to impose necessary restrictions on
parameters of: (1) function f1(t), to ensure “physiologically rea-
sonable” values at each age; (2) the feedback coefficient a(t), to
ensure its negative value at each age so that the trajectories of Yt
tend to f1(t); (3) the baseline hazardμ0(t), to ensure non-negative
values for each age; (4) σ0, and σ1, to ensure non-negative values;
and (5) the quadratic hazard term Q(t), to ensure that the values
are non-negative for each age.
The model was applied to data on the two groups of geno-
typed individuals from the original FHS cohort, those carrying
<14 and ≥14 alleles out of the 27 pro-survival alleles selected
in Yashin et al. (2012c). First, we estimated the unrestricted
model that has all different parameters in the two groups and
then restricted models imposing respective restrictions on the
parameters of the model to test the null hypotheses about the
equality of model’s characteristics in the two groups. Specifically,
we tested four null hypotheses on the equality of (1) baseline
hazards, (2) quadratic hazard terms, (3) adaptive capacities, and
(4) mean allostatic trajectories in the two groups. The hypotheses
were tested using the likelihood ratio test. Respective p-values are
shown in Figures 9–11.
RESULTS
THE NON-MONOTONIC AVERAGE AGE TRAJECTORIES OF
PHYSIOLOGICAL VARIABLES
The shapes of the average age trajectories of physiological indices
(Figure 2) provide useful insights about factors and mechanisms
involved in changes developing in aging human body which
can be verified using more sophisticated statistical approaches.
Figure 2 displays the age patterns of average values of phys-
iological indices for BMI, DBP, SCH, and VR for males and
females combined, evaluated from the data on the Original FHS
cohort.
One can see from this figure that all four trajectories are non-
monotonic. After a period of increase at ages between 35 and
50–54 years, the values of BMI, DBP, SCH, and VR reached their
maximum value and then declined. Note that the shapes of these
curves do not necessarily represent the shapes of biological age
trajectories in individual organisms. This is because in addition
to the contribution of biological aging, these trajectories reflect
the effects of compositional changes due to mortality selection in
a heterogeneous population.
The average age patterns for males and females look similar to
those of the combined estimates, with some differences in details
(not shown). Specifically, the average values of BMI for females
were lower than those of males at ages between 35 and 74 years.
They increased faster and reached their maximum value later than
those of males. After age 75 the values of BMI coincided for the
two genders. The average values of DBP for females were lower
than those of males at ages between 35 and 59. They increased
faster and reached their maximum value later than those of males.
After age 60, the values of DBP practically coincided with those
of males with a tendency to become higher at age 95 years. The
average values of SCH for females were lower than those of males
at ages between 35 and 44 years. Then they became higher than
those of males for the rest of the age domain. The values of SCH
for females increased faster and reached their maximum value
later than those of males. The values of VR for females were higher
than those of males at the entire age domain.
THE AGE TRAJECTORIES OF THE SHORT LIVED (SL) vs. THE LONGEST
LIVED (LL) INDIVIDUALS
Figure 3 shows the average age trajectories of DBP, BMI, SCH,
and VR, for the short lived (lifespan, LS <75 years) and the 100
longest lived (aged 97+) males and females. One can see that tra-
jectories for the LL individuals were substantially different from
those for the SL individuals in all four indices. Specifically, the
average values of BMI were higher among the SL persons until
age 70 with tendency to intersect trajectory of this index for the LL
individuals. The age trajectories of BMI for the SL and LL groups
reached their maximum values at ages 60 and 70, respectively. The
average values of DBP among the SL people were higher than
those of the LL study participants from age 40 until 70 years
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FIGURE 2 | Average trajectories (±standard errors) of four physiological variables in the Framingham Heart Study (original cohort, pooled data from
exams 1–28). (A) Body mass index; (B) diastolic blood pressure; (C) cholesterol; (D) ventricular rate.
FIGURE 3 | Average trajectories (±standard errors) of four
physiological variables in groups of short-lived individuals (“LS
< 75,” i.e., those dying at ages 75 or earlier; censored individuals
are excluded from this group) and 100 longest lived individuals in
the Framingham Heart Study (original cohort, pooled data from
exams 1–28). (A) Body mass index; (B) diastolic blood pressure; (C)
cholesterol; (D) ventricular rate. Symbols above the curves correspond to
p-values for testing the null hypotheses on equality of means in
respective age groups: no symbol: p ≥ 0.05; ∗: 0.01 ≤ p < 0.05;
#: 0.001 ≤ p < 0.01; ! : 0.0001 ≤ p < 0.001; !! : p < 0.0001.
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of age. At ages 70–74 years the values of DBP were practically
indistinguishable between the two groups. The maximum value
of the average DBP in the SL group was higher than that of the LL
persons and it was reached earlier (50 years for the SL and about
60 years for the LL individuals). The average values of SCH were
higher among the SL persons up to age 55, where they reached
their maximum value and then declined. At age 55 the average
age trajectory of SCH for the SL persons intersected that of the LL
persons. The average age trajectory of the SCH for the LL persons
reached their maximum value about age 65 and then declined.
Note that at average, after age 55 females have higher levels of
SCH thanmales. This fact together with information that females
comprise 85% of the LL group and only 57.6% of the SL group
(Table 2) contributes to difference in magnitudes between SCH
trajectories for the SL and LL individuals in Figure 3. The values
of VR for the SL persons were higher until age 65 and then prac-
tically coincided with that of the LL people until age 75 with the
tendency to intersect.
Figure 4 displays individual trajectories for the SL and LL
groups. It reveals that there is some tendency in trajectories of the
LL individuals (to a lesser extent in VR) to avoid extreme values
of indices (which, however, may be just an artifact of a smaller
number of individuals in the LL group). Nevertheless, Figure 4
generally shows that, despite the observed differences in average
patterns (Figure 3), different individuals may have very diverse
trajectories and the SL individuals are a more heterogeneous
group.
THE AGE TRAJECTORIES OF PHYSIOLOGICAL INDICES FOR HEALTHY
AND UNHEALTHY INDIVIDUALS
It is well known from medical practice that health status may
influence values of physiological indices, as well as lifespan.
In turn, physiological variables associated with lifespan are likely
to show associations with some chronic diseases. To elucidate
links between health and physiological variables we calculated
average age trajectories of BMI, DBP, SCH, and VR for healthy
and unhealthy individuals. The unhealthy individuals are defined
here as those having at least one of three diseases: cancer, CVD,
or diabetes. Since having a disease is likely to increase mortality
risk, the unhealthy individuals are likely to be more susceptible
to death. Figure 5 shows average age trajectories for healthy and
unhealthy persons (males and females combined).
One can see from this figure that the trajectories differed for
healthy and unhealthy individuals. Specifically, the average val-
ues of BMI tended to be higher for the unhealthy than for healthy
group at ages from 40 to 95 years. The average trajectories of DBP,
SCH, and VR for healthy and unhealthy persons intersected at
ages between 60 and 70 years. The values of SCH were higher
among unhealthy individuals at age between 40 and 60 years.
Then the curves intersected, so after age 60 the healthy individuals
had higher values of SCH. The values of DBP had a similar pattern
with the intersection point around age 65, which was, however,
less pronounced. The values of VR were higher among unhealthy
people until about age 65, after which they became lower than
those among healthy people.
FIGURE 4 | Individual trajectories of four physiological variables in
groups of short-lived individuals (“SL,” those dying at ages 75 or earlier;
censored individuals are excluded from this group) and 100 longest lived
(“LL”) individuals in the Framingham Heart Study (original cohort,
pooled data from exams 1–28). (A) Body mass index; (B) diastolic blood
pressure; (C) cholesterol; (D) ventricular rate.
www.frontiersin.org January 2013 | Volume 4 | Article 3 | 9
Yashin et al. How longevity genes modulate aging
FIGURE 5 | Average trajectories (±standard errors) of four physiological
variables for “unhealthy” and “healthy” individuals in the Framingham
Heart Study (original cohort, pooled data from exams 1–28). (A) Body
mass index; (B) diastolic blood pressure; (C) cholesterol; (D) ventricular rate.
Note: “unhealthy” individuals are those with cancer, CVD or diabetes;
“healthy” are those free of these three diseases. Measurements of
physiological indices before the onset of any of these diseases contribute to
the “healthy” trajectory and those after the onset of any of the diseases
contribute to the “unhealthy” trajectory. Symbols above the curves
correspond to p-values for testing the null hypotheses on equality of means
in respective age groups: no symbol: p ≥ 0.05; ∗: 0.01 ≤ p < 0.05;
#: 0.001 ≤ p < 0.01; !: 0.0001 ≤ p < 0.001; !!: p < 0.0001.
GENETIC INFLUENCE ON AGE TRAJECTORIES OF PHYSIOLOGICAL
INDICES
In Yashin et al. (2012c), we showed that human lifespan in the
Original FHS cohort was positively associated with the “dose”
of 27 individually selected genetic variants (“longevity” alleles)
each having a small positive effect on lifespan. It is clear that
genetic effects on lifespan and survival are mediated by a num-
ber of intermediate variables whose effects are integrated in the
values of physiological variables. Since the genetic dose index was
associated with lifespan and the values of physiological variables
measured in the Original FHS cohort were also associated with
lifespan we expected that the genetic dose index would show an
association with the age trajectories of the physiological variables
affecting lifespan as well. To illustrate this, we divided the geno-
typed population of study participants into two sub-cohorts. The
first one included individuals carrying up to 13 out of 27 alle-
les associated with lifespan in our earlier study. Individuals from
the second sub-cohort carry 14 and more such alleles in their
genomes, referred as the (<14)- and the (≥14)-groups, respec-
tively. Figure 6 shows how the age trajectories of BMI, DBP, SCH,
and VR differed between the (<14)- and the (≥14)-groups of
study participants for the two genders combined.
One can see from this figure that the average age trajectories
of BMI for the (<14)-group were higher up to age 65 years and
then became lower than those in the (≥14)-group. Note that the
maximum value of BMI for the members of (<14)-group was
reached earlier (around 55 years of age) than for the members
of the (≥14)-group (around 75 years). The individuals from the
(<14)-group had higher levels of the average values of DBP and
VR for the entire age interval 35–95 years shown in the graphs.
The average values of the SCH for this group were higher than
those for the (≥14)-group between ages 50 and 95 years and were
about the same beyond this interval.
The average age trajectories of these physiological indices var-
ied slightly between males and females (figures not shown).
Specifically, the average values of BMI among female members
of the (<14)-group were higher until age 70, stayed about the
same until age 85, and intersected those of the group (≥14)
after this age. In males, the values of this variable tended to
be higher in the (<14)-group until age 60, became lower than
those in the (≥14)-group and then became about the same at
age 85 years. For DBP the pattern of differences between the two
groups remained the same for each of the two genders with larger
differences in DBP trajectories between the groups in females
than in males. In males, the values of VR in the two groups
were about the same until age 50 years and then diverged. The
female levels of SCH in the (<14)-group were higher than in
the (≥14)-group until age 85 and were about the same after this
age. In males, the values of SCH remained higher in this group
until age 50, stayed about the same in both groups until age
75, and then they become lower for the members of the (<14)-
group. For comparison we will show age patterns of the same
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FIGURE 6 | Average trajectories (±standard errors) of four
physiological variables in the Framingham Heart Study (original
cohort, pooled data from exams 1–28) for individuals carrying
different number of pro-survival alleles (<14 and ≥14) out of
the 27 such alleles identified in Yashin et al. (2012c). (A) Body mass
index; (B) diastolic blood pressure; (C) cholesterol; (D) ventricular rate.
Symbols above the curves correspond to p-values for testing the null
hypotheses on equality of means in respective age groups: no symbol:
p ≥ 0.05; ∗:0.01 ≤ p < 0.05; #:0.001 ≤ p < 0.01; !: 0.0001 ≤ p < 0.001;
!!: p < 0.0001.
physiological variables for carriers and non-carriers of the APOE-
e4 allele.
THE AGE TRAJECTORIES OF PHYSIOLOGICAL INDICES FOR CARRIERS
AND NON-CARRIERS OF THE APOE-e4 ALLELE
The association of the APOE alleles with longevity has been
detected in many genetic studies (e.g., Deelen et al., 2011; Nebel
et al., 2011). Their influences on age trajectories of physiological
indices are less known. In Arbeev et al. (2012) we evaluated effects
of the APOE polymorphism on age trajectories of SCH and DBP
in the original FHS cohort and found differences in average age
trajectories of these indices in long-lived carriers and non-carriers
of the e4 allele. The analyses also showed that the average age tra-
jectories in individuals dying at earlier agesmarkedly deviate from
those of the long-lived groups and these patterns differ for carri-
ers and non-carriers of the e4 allele of both sexes. Applying the
extended version of the stochastic process model (Arbeev et al.,
2009) we found the presence of a genetic component in aging-
related mechanisms that is manifested in the observed patterns
of the allele-specific age trajectories of physiological indices and
mortality rates.
To compare whether the effects of the APOE alleles are similar
to those of genetic variants we calculated average age trajectories
of the BMI, DBP, SCH, and VR for study participants carrying
and not carrying APOE-e4 allele. These trajectories are shown in
Figure 7 for males and females combined.
One can see from this figure that the values of DBP and VR
were about the same for carriers and non-carriers of APOE-e4.
The most significant difference was in BMI. The curves look
about the same until age 65, and then diverge. Among the APOE-
e4 carriers, BMI starts to decline. Among non-carriers the values
of BMI continued to increase until age 75 and then declined. The
rate of decline was higher among carriers of the APOE-e4. The
SCH levels were about the same until age 50, after which they
became higher in the carriers of the APOE-e4 and remain slightly
higher for the rest of the age interval. The figures for males and
females are not much different from combined estimates (the
graphs are not shown). The figures for females repeat those for the
two sexes combined. For males, the values of DBP among APOE-
e4 carriers were slightly lower than in non-carriers until age 55,
stayed about the same until age 75, and then slightly exceeded
those of non-carriers. Comparing Figure 7 with Figure 6 indi-
cates that the effect of the APOE-e4 on SCH is similar to that of
the (<14)-group at the entire age domain; for BMI the effect is
similar after age 65; for DBP the effect is opposite but much less
pronounced; and for VR the APOE-e4 effect does not exist.
GENETICS OF AGE TRAJECTORIES FOR HEALTHY AND UNHEALTHY
INDIVIDUALS
The graphs of the age trajectories of BMI, DBP, SCH, and VR for
unhealthy individuals of the (<14)- and (≥14)-groups are shown
in Figure 8 for the two sexes combined.
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FIGURE 7 | Average trajectories (±standard errors) of four physiological
variables for carriers (“e4”) and non-carriers (“not e4”) of the APOE e4
allele in the Framingham Heart Study (original cohort, pooled data
from exams 1–28). (A) Body mass index; (B) diastolic blood pressure;
(C) cholesterol; (D) ventricular rate. Symbols above the curves correspond to
p-values for testing the null hypotheses on equality of means in respective
age groups: no symbol: p ≥ 0.05; ∗:0.01 ≤ p < 0.05; #:0.001 ≤ p < 0.01;
! :0.0001 ≤ p < 0.001; !! : p < 0.0001.
The average values of BMI in the (<14)-group were higher
than those in the (≥14)-group until age 65. Then the trajecto-
ries intersected so the values of BMI in the (<14)-group became
smaller than those in the (≥14)-group for the rest of the age
domain. The average values of DBP in both groups were about the
same between ages 65 and 75 years. However, beyond this inter-
val the values of this index in the (<14)-group were higher than
those in the (≥14)-group. The average levels of SCH were about
the same until age 65. Then they become higher in the (<14)-
group until age 95 years. The average values of VR were about the
same until age 55 and then became higher for individuals from
the (<14)-group.
The graphs of the age trajectories of BMI, DBP, SCH, and VR
for healthy individuals of the (<14)- and (≥14)-groups for the
two sexes combined practically repeat those shown in Figure 6
for the entire population and therefore are not shown.
THE EFFECTS OF GENETIC DOSE ON MORTALITY BY CAUSE
The results of application of the Cox model to cause-specific mor-
tality data (see details in section “Empirical analyses”) are shown
in Table 3. One can see from this table that the estimates of the
effects on all mortality rates are statistically significant.
THE NEED FOR COMPREHENSIVE INTEGRATIVE ANALYSES OF
LONGITUDINAL DATA
The values of physiological variables described above are regu-
lated by dynamic biological mechanisms which integrate external
influence, internal changes and compensatory activity. An essen-
tial part of such mechanism is the negative feedback loop which
tends to stabilize the values of regulated variables around cer-
tain set points. Many variables involved in regulation of observed
physiological indices are not observed, and therefore are not rep-
resented in the longitudinal data. To be able to address research
questions about fundamental regularities of changes developing
in aging human body, the behavior of these additional variables
has to be investigated together with the values of physiological
variables measured in the study. For these purposes we developed
a version of the stochastic process model of human mortality
and aging which allows for incorporating established facts, new
research findings, and a number of theoretical concepts about
aging into the model. Specifically, we used linear stochastic differ-
ential equations to describe aging related changes in physiological
variables driven by the effect of allostatic adaptation to persis-
tent external disturbances, stochastic components, and subjected
to regulation by negative feedback mechanism, which proper-
ties may change during the life course. The dynamic effects of
physiological variables on mortality risk are described by con-
ditional hazard having quadratic form. This reflects empirical
evidence of the U- or J-shapes of risks considered as func-
tions of risk factors (e.g., observed covariates). Variables describ-
ing changes in stress resistance and adaptive capacity modulate
quadratic hazard and feedback regulation mechanism, respec-
tively. Variables describing physiological norm characterize “opti-
mal” values of conditional risks. Additional variables characterize
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FIGURE 8 | Average trajectories (±standard errors) of four
physiological variables in the Framingham Heart Study (original
cohort, pooled data from exams 1–28) for “unhealthy” individuals
carrying different number of pro-survival alleles (<14 and ≥14) out of
the 27 such alleles identified in Yashin et al. (2012c). (A) Body mass
index; (B) diastolic blood pressure; (C) cholesterol; (D) ventricular rate.
Note: “unhealthy” individuals are those with cancer, CVD, or diabetes;
“healthy” are those free of these three diseases. Measurements of
physiological indices before the onset of any of these diseases contribute
to the “healthy” trajectory and those after the onset of any of the
diseases contribute to the “unhealthy” trajectory. Symbols above the
curves correspond to p-values for testing the null hypotheses on
equality of means in respective age groups: no symbol: p ≥ 0.05;
∗: 0.01 ≤ p < 0.05; #: 0.001 ≤ p < 0.01; !: 0.0001 ≤ p < 0.001; !! : p < 0.0001.
Table 3 | Effects of polygenic score on total and cause-specific mortality in the Cox model.
Cause Events # Cens. # Beta SE p-value HR (95% C.I.)
Total 1267 204 −0.057 0.007 2.7E-18 0.94 (0.93; 0.96)
CVD 368 1103 −0.047 0.012 0.0001 0.95 (0.93; 0.98)
Cancer 243 1228 −0.030 0.015 0.041 0.97 (0.94; 0.99)
Other 656 815 −0.071 0.009 1.9E-15 0.93 (0.92; 0.95)
Notes: “Cause” denotes the cause of death (Total—all causes, CVD, cancer, and Other—all other causes or unknown cause); “Events #” shows the number of
deaths from specific cause; “Cens. #” indicates the number of censored cases; “Beta” shows the estimate of the regression coefficient for the polygenic score
variable in the Cox model; “SE” is a standard error for Beta; “p-value” characterizes the significance of the estimate; “HR” shows the estimate of hazard ratio per
one SNP (pro-survival allele), 95% confidence intervals are shown in parentheses.
levels of stochasticity and effects of allostatic adaptation (Yashin
et al., 2007a, 2012a).
The traditional way of describing dynamics of systems with
such regulation is the use of ordinary differential equations. To
take the random factors that tend to shift the values of corre-
sponding variables from their normal set points into account,
the stochastic differential equation with feedback is used (Yashin
and Manton, 1997; Yashin et al., 2007a). In the ideal (no stresses)
situation the set point of the feedback regulation mechanism
for a given variable corresponds to its normal value for a given
age, i.e., the value that minimizes mortality risk at this age. In
the presence of persistent external disturbances the regulation set
point deviates from its normal value by the process of allostatic
adaptation. The absolute value of difference between the normal
and the realized set points is called allostatic load. The allostatic
load may change with age reflecting continuing adjustment of an
organism to persistent environmental conditions. Note that nei-
ther these conditions nor allostatic load are observed, although a
number of studies developed a proxy measure of these character-
istics using available measurements (McEwen and Seeman, 1999;
McEwen, 2000, 2012). In our analyses the variable representing
allostatic load can be introduced into the model and estimated
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indirectly from longitudinal data. The quality of feedback reg-
ulation is determined by the absolute value of the feedback
coefficient. This value characterizes the “adaptive capacity” of a
system. Individuals with better capacity are likely to be healthier
and have longer life.
Two mechanisms regulating average values of the physiological
index in the cohort
It is shown by Yashin et al. (2007a) that average trajectories of
any physiological index (m(t)) described by Equations (1) and
(2) satisfy the following ordinary differential equation:
dm(t)/dt = a(t)(m(t) − f1(t)
) − 2γ(t)Q(t)(m(t)
− f0(t)
)
,m(0) = m0 (3)
Here the coefficient γ(t) is a positive function of age (Yashin
et al., 2007a), and all other coefficients are specified in the
descriptions of Equations (1) and (2). The coefficient a(t) is
negative by the definition. The coefficient Q(t) is non-negative
by definition. Thus equation (3) describes two negative feed-
back mechanisms regulating age trajectory of m(t). One of them,
characterized by the feedback loop coefficient a(t), deals with
homeostatic adaptation to the values of slow-time allostatic
response f1(t) to persistent external disturbances (e.g., stresses
of life). This mechanism tries to keep the value of m(t) around
function f1(t). The second mechanism is represented by the
negative feedback loop describing the effect of mortality selec-
tion on m(t) (average age trajectory of physiological index).
This mechanism is characterized by the feedback coefficient
−2γ(t)Q(t). Its task is to keep the value of m(t) around func-
tion f0(t), the optimal age trajectory of physiological index, (i.e.,
the function of age which minimizes the mortality risk at each
given age).
Application to data
The version of this general model has been used in the analyses
of data on four physiological indices (BMI, DBP, SCH, and VR)
collected in the Original FHS cohort (see section “Advanced sta-
tistical analyses using the stochastic process model”). The results
of these analyses of longitudinal data are shown in Figures 9–11.
One can see from these figures that parameters of corresponding
models are successfully estimated, and age trajectories of cor-
responding variables can be well interpreted. Substantially, the
analyses revealed significant differences in the parameters of the
model associated to the baseline hazard rates (except SCH), the
adaptive capacities (except VR) and the average allostatic trajec-
tories between the two sub-groups of individuals carrying <14
and ≥14 pro-survival alleles.
Figure 9 shows that the baseline hazard (i.e., the hazard sum-
marizing the effect of all factors except respective physiological
variable) is lower in carriers of a larger number of pro-survival
alleles (≥14), compared to carriers of a smaller number of such
alleles (<14) for all variables except SCH.
The lack of significant differences in the baseline hazard rates
for SCH indicates that the differences in survival chances in the
two groups can be explained by differences in other characteristics
such as adaptive capacities and average allostatic trajectories
(see Figures 10C and 11C). Note also that for two indices, DBP
and VR, the initial value of the baseline hazard is smaller but its
slope is larger in carriers of a larger number of alleles (≥14) and
the curves intersect at some advanced age (around 105 years).
This means rectangularization of respective “baseline” survival
functions (when going from the (<14)- to the (≥14)-group). We
note here that the results for BMI should be interpreted with care
because the quadratic term for the (<14)-group estimated as zero
for this index (data not shown).
Figure 10 displays the estimates of the feedback coefficient
representing adaptive capacity in the model.
It reveals that for two physiological variables, DBP and SCH,
carriers of a larger number of pro-survival alleles have signif-
icantly better adaptive capacity [i.e., larger absolute values of
the feedback coefficient in Equation (1)] than individuals with
a smaller number of such alleles. That is, in the group carrying
a larger number of pro-survival alleles, the trajectories of these
physiological variables return faster to the average “allostatic” tra-
jectories that organisms are forced to follow than they do in the
individuals carrying a smaller number of pro-survival alleles.
Figure 11 shows these average trajectories that the organisms
are forced to follow by the process of allostatic adaptation (“mean
allostatic trajectories”) in the two groups.
One can see from this figure that the processes of allo-
static adaptation in individuals carrying different number of
pro-survival alleles act differently in the sense that the resulting
trajectories are significantly different in the two groups. The pat-
tern differs by physiological variables. Specifically, the trajectory
for the (<14)-group is consistently lower for BMI, consistently
higher for VR, and shows similar patterns for the other two
variables (DBP and SCH): for the (<14)-group the trajectory
is initially higher, reaches the maximum and starts declining at
earlier ages, and declines at a faster rate compared to the (≥14)-
group so that the trajectories in the two groups intersect at ages
about 90–95. Finally, we observed that the (≥14)-group has a
decline in the quadratic hazard termQ(t) with age which means a
widening [not narrowing as in the (<14)-group] U-shape of the
mortality risk as a function of a physiological variable with age.
However, no significant conclusion can be made about the differ-
ence in behavior of the quadratic hazard term in these two groups
for all physiological variables because of non-significant p-values
(about 0.4) and we do not show the results here.
In sum, the evaluated hidden mechanisms of aging-related
changes can collectively explain the difference in the mortality
risk in the two groups carrying different number of pro-survival
alleles. Note that these analyses illustrate the effect of only spe-
cific longitudinal variables. As the significant differences between
baseline hazard rates in the two groups reveal, there can be many
more factors that can explain the difference in the mortality rates
in these groups.
DISCUSSION
EXTREME LONGEVITY AND HEALTH ARE LINKED TO DISTINCT TYPES
OF CHANGES IN AGE-TRAJECTORIES OF PHYSIOLOGICAL INDICES
Figures 3 and 5 indicate that exceptional longevity and health
may be linked to distinct types of changes in the age-trajectories of
physiological indices. Indeed, a common point of the differences
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FIGURE 9 | Estimates of the logarithm of the baseline hazard rates in the
stochastic process model (Yashin et al., 2007a) applied to data on
longitudinal measurements of four physiological indices and total
mortality in individuals carrying different number of pro-survival alleles
(<14 and ≥14) out of the 27 such alleles identified in Yashin et al.
(2012c). (A) Estimates for body mass index (BMI); (B) estimates for diastolic
blood pressure (DBP); (C) estimates for cholesterol (SCH); (D) estimates for
ventricular rate (VR). P -values are for the null hypotheses on the equality of
baseline hazards in the two groups. See more details about the model in
section “Advanced statistical analyses using the stochastic process model.”
between the longest versus shorter living individuals, as seen in
Figure 3, is that for the LL individuals the value of an index peaked
later in life and started to decline about 10 years later as compared
with the SL individuals. For BMI, in particular, the patterns of its
aging changes had similar shape for the LL and SL, as well as had
similar peak values of the index. The major difference was that for
the LL individuals, the whole age-pattern of the BMI was shifted
to the right, and all BMI changes were postponed in time.
This indicates that a postponement of physiological aging
changes in time may be essential for achieving extreme longevity.
It seems logical, especially if to look at strains of lab animals which
significantly differ in longevity and are thought to age at a differ-
ent pace [such as B6 vs. DBAmice, e.g., Sell andMonnier (1997)].
The longer compared to shorter living strains typically have all the
stages of aging changes in physiological indices (such as the rise,
peak or decline in BMI) shifted toward an older age (Turturro
et al., 1999).
While the typical difference between the long and short liv-
ing individuals was the shift of the age-trajectory of physiological
changes toward older age, the respective trajectories for healthy
and unhealthy individuals had similar timing and overall similar
age at the peak value of the index, with probable exception for
cholesterol (Figure 5).
Our results thus suggest that pathways to achieving extreme
longevity and health are not necessary the same, or at least do
not always overlap and may potentially involve significant trade-
offs. For example, consider BMI in Figures 3 and 5. Why indeed
is the average BMI in healthy old people substantially lower than
that BMI in the longest living individuals for similar age intervals
75 + ? One reason could be that at older ages (and especially at
the oldest old ages), the level of overall resistance to stresses (such
as ability to cope with infections, fractures, bleeding, sarcopenia,
atrophy, and generally frailty) starts to play a more important
role in person’s survival than specific diseases. This is reflected in
declining the relative excess ofmortality attributed to each specific
cause of death with advancing age (Forsen et al., 1999; Horiuchi
et al., 2003; Richmond et al., 2003). And as it was discussed at a
recent International Conference on Sarcopenia Research, having
an excess of fat storage in the body may potentially help to post-
pone frailty and improve the relative chances of survival in both
healthy and unhealthy individuals at older ages (Doehner et al.,
2012).
Figure 3 shows that longest lived subjects have significantly
higher SCH levels, which seems to contradict with the general
knowledge from epidemiological studies that higher SCH levels
are associated with a higher mortality. Although the literature
analyses show controversial results the evidence is accumulat-
ing that the values of total cholesterol have different effects at
different age intervals. Specifically, Kronmal et al. (1993) found
that the relationship between total cholesterol level and all-cause
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FIGURE 10 | Estimates of adaptive capacity in the stochastic
process model (Yashin et al., 2007a) applied to data on longitudinal
measurements of four physiological indices and total mortality in
individuals carrying different number of pro-survival alleles (<14 and
≥14) out of the 27 such alleles identified in Yashin et al. (2012c).
(A) Estimates for body mass index (BMI); (B) estimates for diastolic blood
pressure (DBP); (C) estimates for cholesterol (SCH); (D) estimates for
ventricular rate (VR). P -values are for the null hypotheses on the equality of
adaptive capacities in the two groups. See more details about the model in
section “Advanced statistical analyses using the stochastic process model.”
mortality was positive at age 40 years, negative at age 80 years, and
negligible at ages 50–70 years. Krumholz et al. (1994) concluded
that the results of their analyses do not support the hypothe-
sis that hypercholesterolemia or low HDL-C are important risk
factors for all-cause mortality, coronary heart disease mortality,
or hospitalization for myocardial infarction or unstable angina
in this cohort of persons older than 70 years. Weijenberg et al.
(1996) reported that total cholesterol seems to be a stronger
risk factor for mortality from the disease, whereas HDL choles-
terol is more strongly associated with the incidence of a first
coronary heart disease event. Weverling-Rijnsburger et al. (1997)
concluded that in people older than 85 years, high total choles-
terol concentrations are associated with longevity owing to lower
mortality from cancer and infection. Chyou and Eaker (2000)
reported that an increased ratio of total cholesterol to high-
density lipoprotein appears to be associated with an increase
in risk for all-cause mortality in men aged 65 and over, while
an elevated level of high-density lipoprotein, considered alone,
seems to be protective against mortality from all causes in men
aged 65–74 years, but this effect diminishes over the age of 75.
Karlamangla et al. (2004) reported that increases in cholesterol
over time have beneficial associations in some older adults. The
authors concluded that the role of cholesterol changes in the
health of older individuals needs further exploration. Upmeier
et al. (2009) concluded that high levels of serum total cholesterol
and particularly low levels of HDL-C seem to be risk factors for
cardiovascular mortality even in the elderly population. Newson
et al. (2011) found that higher total cholesterol was associ-
ated with a lower risk of non-cardiovascular mortality in older
adults. This association varied across the late-life span and was
stronger in older age groups. The authors concluded that further
research is required to examine the mechanisms underlying this
association.
Several recent studies in Japan reported that all-cause mor-
tality among individuals with the highest total cholesterol levels
was lower than in the other individuals (Ogushi and Kurita, 2008;
Noda et al., 2010; Nago et al., 2011; Hamazaki et al., 2012a).
Hamazaki et al. (2012b) reported that almost all epidemiolog-
ical studies in Japan showed that all-cause mortality was lower
in subjects with high levels of total cholesterol. Our results in
Figure 3 for age trajectories of SCH levels among long-lived and
short lived individuals support Japanese finding. The biologi-
cal mechanisms responsible for such connection require separate
study.
GENES INFLUENCING LIFESPAN MAY BE A MIX OF VARIANTS
FAVORING EXTREME LONGEVITY AND HEALTH
A comparative look at Figures 3, 5, and 6 indicates that the 27
SNP alleles associated with lifespan influence the age trajectories
of physiological indices in this study in complex ways involving
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FIGURE 11 | Estimates of mean allostatic trajectories in the stochastic
process model (Yashin et al., 2007a) applied to data on longitudinal
measurements of four physiological indices and total mortality in
individuals carrying different number of pro-survival alleles (<14 and≥14)
out of the 27 such alleles identified in Yashin et al. (2012c). (A) Estimates
for body mass index (BMI); (B) estimates for diastolic blood pressure (DBP);
(C) estimates for cholesterol (SCH); (D) estimates for ventricular rate (VR).
P -values are for the null hypotheses on the equality of mean allostatic
trajectories in the two groups. See more details about the model in section
“Advanced statistical analyses using the stochastic process model.”
both health and aging related processes. This is because all types
of the effects seen in Figures 3 and 5 appear in the Figure 6,
including the parallel shift of the age trajectory of an index to
the right (for BMI); the same age at the peak value but different
levels of an index at the peak (for DBP and SCH); and differ-
ent rates of decline in the index value at older ages (for VR).
This means that some of the 27 pro-survival alleles may modu-
late predisposition to particular diseases, some may regulate the
rate and onset of physiological aging changes, and some other
may have pleiotropic influence on respective traits. These results
are in agreement with our earlier analysis of the functional effects
of genes linked to the 27 SNPs, where we found that such genes
are involved in both physiological aging and common diseases
(Yashin et al., 2012c).
Note that we did not match the (<14)- and (≥14)-groups of
the study subjects for other confounding factors. This is because
we would like to show how age trajectories of physiological indices
differ for individuals carrying different numbers of “pro-survival”
genetic variants. The age patterns of physiological change for
human individuals with different genetic background have never
been studied before. These results do not pretend to be inter-
preted as causal relationships. They, however, help researchers
get useful insights and ideas on how such relationship could
be evaluated in future studies. The effects of genetic and non-
genetic factors on dynamics of each physiological variable deserve
separate analyses.
NON-MONOTONIC CHANGES IN PHYSIOLOGICAL INDICES
Our analyses showed that the population average trajectories of
BMI, DBP, SCH, and VR, as well as their average biological age
trajectories (at least for the LL individuals), are non-monotonic.
This property of aging-related changes may reflect the decline in
functioning of various tissues and organs involved in the regula-
tion of these variables. This means that the difference in the ages
at which a given variable reached its maximum value in different
groups of individuals might provide us with useful information
about the rates of aging in these groups. The links of this param-
eter with lifespan and healthy lifespan were established in Yashin
et al. (2010a). Several other characteristics of dynamic behavior
of age trajectories of biological indices were also associated with
lifespan. These include the average values, as well as the slopes
and intercepts of physiological indices calculated between ages 40
and 60 years, the value of the maximum, the rate of decline after
reaching the maximum value and the individual variability of an
index during the life course (Yashin et al., 2006, 2010a).
The non-monotonic age patterns of physiological variables
present additional challenges for those who seek biomarkers of
aging capable of measuring “biological” age. The indices inves-
tigated above are not good for that. This is because of the
non-linear changes of their values with age, e.g., they can be
about the same at ages 45–50 and 85–90 years. It is important
to note that the forces driving the average age trajectories of
physiological variables cannot be detected from the data using
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standard statistical methods. These mechanisms, however, can be
described and their characteristics can be estimated from the data
using advanced methods of statistical modeling, see Yashin et al.
(2012a) and references therein. Two possible mechanisms con-
tributing to corresponding shapes have been proposed (Yashin
et al., 2010b). The first one deals with biological homeostatic
regulation of the values of physiological variables in response
to aging related changes, and to persistent external challenges.
This mechanism is represented by the first term in Equation
(3). The second mechanism deals with mortality selection in
heterogeneous populations in which individuals with high devi-
ations of physiological variables from the norm have substan-
tially higher mortality risks. The deceased individuals, as well
as those who leave the study for other reasons at some age,
drop out of the averaging procedure after this age. This part
of the mechanism is represented by the second term in the
Equation (3).
To evaluate the shape of the biological age trajectories without
compositional changes and to compare whether the age trajecto-
ries of individuals having long lifespan differ from those who died
prematurely, we dividedmembers of the Original FHS cohort into
the two sub-cohorts of the SL and LL individuals. The LL indi-
viduals included all those whose lifespan exceed 97 years. The
results of our analyses indicated that biological age trajectories
of the four physiological variables studied in this paper were non-
monotonic. Typically the SL persons had initially higher average
values of these indices. The average age trajectories for the SL
persons reached their maximum values, and started to decline
earlier than those of the LL persons. The average age trajecto-
ries of the LL persons describe their average biological changes
until about age 97, and these changes were non-monotonic. The
fact that these trajectories differed substantially for the SL and LL
groups of individuals indicates that they contain useful informa-
tion about remaining lifespan distributions which could be used
for predicting this trait.
INTERSECTION OF THE AGE TRAJECTORIES FOR HEALTHY AND
UNHEALTHY PERSONS
The fact that average age trajectories of DBP, SCH, and VR for
healthy and unhealthy individuals intersect may indicate funda-
mental aging related changes occurring on the way from the old
to the oldest old ages. Such a transition is likely to rearrange fac-
tors of susceptibility to diseases and change the role of risk factors
from deleterious to neutral or even favorable. These intersections,
however, do not explain what kind of forces might be responsi-
ble for such behaviors of these curves. One possibility is that the
genetic factors could contribute to observed patterns.
The genetic analyses of the age trajectories of the four indices
indicate that the genetic influence of pro-survival alleles may dif-
fer from one index to the next. For example, the effect of the
(<14)- and (≥14)-groups on BMI differs from those on DBP and
VR, and the effects of these genetic groups on SCH are similar
to these two but the effects on SCH become more pronounced
only after age 50. This indicates that studying the roles of genes
in aging related changes requires more information about biolog-
ical mechanisms involved in regulation of these characteristics.
Analyses of genetic influence on age patterns of average phys-
iological indices for healthy and unhealthy individuals resulted
in similar conclusions. They also showed that the selected pro-
survival alleles were likely to contribute to mortality from CVD
and cancer.
THE USE OF STOCHASTIC PROCESS MODEL IN ANALYSES OF
LONGITUDINAL DATA
The statistical analyses of longitudinal data using stochastic pro-
cess model allowed us to evaluate hidden dimensions of aging
related changes which are important for better understanding
regulatory mechanisms driving observed aging related changes in
physiological variables. The hidden components of aging related
changes incorporated into our model include adaptive capacity,
resistance to stresses, physiological norm, and the effect of allo-
static adaptation [see notations for variables used in Equations
(1) and (2)]. All these variables play important role in the aging
process but were not directly measured in longitudinal data. The
adaptive capacity characterizes the ability of organisms to keep
the values of physiological variable around set-point of home-
ostatic regulation. The higher absolute values of this variable
correspond to better organism’s capacity to adapt and provide it
with better fitness. Physiological norm describes optimal value of
physiological variable which minimizes mortality risk. The resis-
tance to stresses characterizes sensitivity of mortality risk to the
deviation of physiological variable from the norm. The effect
of allostatic adaptation characterizes set-point in mechanism of
homeostatic regulation of physiological index. This component
of physiological change integrates influence of persistent exter-
nal disturbances. Note that since external disturbances are not
measured in most of longitudinal studies, the estimates of the dif-
ference between this variable and physiological norm (allostatic
load) may serve as an important indicator of healthy or unhealthy
environment individuals under study are exposed to. Our analy-
ses show that these characteristics can be estimated from the data
using stochastic process model of human mortality and aging.
The use of such model allows for testing statistical hypotheses not
only about genetic influence on age trajectories of physiological
indices but also about the roles of genes in mechanisms involved
in regulation of these trajectories.
CONCLUSIONS
The age trajectories of physiological indices corresponding to
individuals with exceptional longevity differ from those of people
living without three major human diseases—cancer, CVD, and
diabetes. These results may indicate that factors responsible for
the long life and good health are not necessary the same. The
trajectories for long-living individuals look as if their age related
changes were postponed compared to persons died prematurely.
The analyses confirmed that genetic influences on lifespan
are realized through dynamic mechanisms regulating changes in
physiological variables during the life course as well as through
variables describing individual health status. The genetic dose
index constructed from genetic variants selected for their individ-
ual associations with lifespan showed association with mortality
rates by cause. This indicates that these genetic factors influence
both health and lifespan.
The average aging related changes in the four selected physio-
logical variables are likely to be driven by hidden components of
aging changes and by genetic factors.
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The ability of advanced methods of statistical model-
ing to estimate hidden components of aging changes in
humans indicates that the approach can be further extended
to perform more comprehensive analyses of available data
by incorporating relevant biological knowledge about aging
into statistical models. The use of such models in statistical
analyses of data will help researchers to untangle complex age-
dependent dynamic relationships among biomarkers and eluci-
date roles of genes and non-genetic factors in aging, health, and
lifespan.
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